{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T15:00:08Z","timestamp":1761663608617},"reference-count":34,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,17]],"date-time":"2017-04-17T00:00:00Z","timestamp":1492387200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Kaohsiung Medical University Hospital","award":["KMUH103-10V04","KMUH103-3R04"],"award-info":[{"award-number":["KMUH103-10V04","KMUH103-3R04"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","jfma-online.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.jfma.2017.06.006","type":"journal-article","created":{"date-parts":[[2017,6,27]],"date-time":"2017-06-27T02:01:41Z","timestamp":1498528901000},"page":"518-526","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Paritaprevir\/ritonavir\/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1\u00a0infection after liver transplantation: Real-world experience"],"prefix":"10.1016","volume":"117","author":[{"given":"Ming-Lung","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao-Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chung-Feng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuo-Hua","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Lun","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-I.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-Hsuan","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zu-Yau","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinn-Cherng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jee-Fu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Yen","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan-Long","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jfma.2017.06.006_bib1","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/hep.26972","article-title":"Evaluation for liver transplantation in adults: 2013 practice guideline by the American association for the study of liver diseases and the American society of transplantation","volume":"59","author":"Martin","year":"2014","journal-title":"Hepatol (Baltimore, MD)"},{"issue":"6","key":"10.1016\/j.jfma.2017.06.006_bib2","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/jvh.12534","article-title":"Treat chronic hepatitis C virus infection in decompensated cirrhosis - pre- or post-liver transplantation? the ironic conundrum in the era of effective and well-tolerated therapy","volume":"23","author":"Bunchorntavakul","year":"2016","journal-title":"J Viral Hepat"},{"issue":"5","key":"10.1016\/j.jfma.2017.06.006_bib3","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s12072-016-9744-3","article-title":"Management of post liver transplantation recurrent hepatitis C infection with directly acting antiviral drugs: a review","volume":"10","author":"Jothimani","year":"2016","journal-title":"Hepatol Int"},{"issue":"6","key":"10.1016\/j.jfma.2017.06.006_bib4","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1473-3099(16)00120-1","article-title":"New perspectives for preventing hepatitis C virus liver graft infection","volume":"16","author":"Felmlee","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.jfma.2017.06.006_bib5","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1053\/j.gastro.2007.03.041","article-title":"Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study","volume":"132","author":"Carrion","year":"2007","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.jfma.2017.06.006_bib6","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1600-6143.2007.02126.x","article-title":"Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation","volume":"8","author":"Berenguer","year":"2008","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg"},{"issue":"2","key":"10.1016\/j.jfma.2017.06.006_bib7","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jhep.2008.05.002","article-title":"Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin","volume":"49","author":"Berenguer","year":"2008","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.jfma.2017.06.006_bib8","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/j.1600-6143.2006.01362.x","article-title":"Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis","volume":"6","author":"Wang","year":"2006","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg"},{"issue":"10","key":"10.1016\/j.jfma.2017.06.006_bib9","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1365-2893.2008.01019.x","article-title":"Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies","volume":"15","author":"Xirouchakis","year":"2008","journal-title":"J Viral Hepat"},{"issue":"5","key":"10.1016\/j.jfma.2017.06.006_bib10","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/hep.28446","article-title":"Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence","volume":"63","author":"Poordad","year":"2016","journal-title":"Hepatol (Baltimore, MD)"},{"issue":"6","key":"10.1016\/j.jfma.2017.06.006_bib11","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1473-3099(16)00052-9","article-title":"Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial","volume":"16","author":"Manns","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.jfma.2017.06.006_bib12","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","article-title":"Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease","volume":"149","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"issue":"25","key":"10.1016\/j.jfma.2017.06.006_bib13","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1056\/NEJMoa1408921","article-title":"An interferon-free antiviral regimen for HCV after liver transplantation","volume":"371","author":"Kwo","year":"2014","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.jfma.2017.06.006_bib14","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","article-title":"Treatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Feld","year":"2014","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.jfma.2017.06.006_bib15","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJMoa1401561","article-title":"Retreatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.jfma.2017.06.006_bib16","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis","volume":"370","author":"Poordad","year":"2014","journal-title":"N. Engl J Med"},{"issue":"5","key":"10.1016\/j.jfma.2017.06.006_bib17","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/ajt.13111","article-title":"Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir","volume":"15","author":"Badri","year":"2015","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg"},{"issue":"1","key":"10.1016\/j.jfma.2017.06.006_bib18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","article-title":"EASL recommendations on treatment of hepatitis C 2016","volume":"66","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2017.06.006_bib19","unstructured":"HCV guidance: recommendations for testing, managing, and treating Hepatitis C. http:\/\/www.hcvguidelines.org\/. [Accessed 22 October 2016]."},{"issue":"5","key":"10.1016\/j.jfma.2017.06.006_bib20","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s12072-016-9717-6","article-title":"APASL consensus statements and recommendation on treatment of hepatitis C","volume":"10","author":"Omata","year":"2016","journal-title":"Hepatol Int"},{"issue":"2","key":"10.1016\/j.jfma.2017.06.006_bib21","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jcv.2011.07.007","article-title":"Multi-center evaluation of the Abbott RealTime HCV assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C","volume":"52","author":"Vermehren","year":"2011","journal-title":"J Clin Virol Off Publ Pan Am Soc Clin Virol"},{"issue":"12","key":"10.1016\/j.jfma.2017.06.006_bib22","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1038\/ajg.2011.341","article-title":"Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C","volume":"106","author":"Rizzo","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.jfma.2017.06.006_bib23","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","year":"2015","journal-title":"Hepatol (Baltimore, MD)"},{"issue":"1","key":"10.1016\/j.jfma.2017.06.006_bib24","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"EASL recommendations on treatment of hepatitis C 2015","volume":"63","year":"2015","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.jfma.2017.06.006_bib25","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1002\/hep.27770","article-title":"Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant","volume":"61","author":"Pungpapong","year":"2015","journal-title":"Hepatol (Baltimore, MD)"},{"issue":"27","key":"10.1016\/j.jfma.2017.06.006_bib26","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jfma.2017.06.006_bib27","first-page":"1367","article-title":"Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3\/F4) after liver transplantation: results from the CO23 ANRS CUPILT study","volume":"22","author":"Dumortier","year":"2016","journal-title":"Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc"},{"issue":"1","key":"10.1016\/j.jfma.2017.06.006_bib28","first-page":"24","article-title":"Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: real-world experience from the hepatitis C therapeutic registry and research network","volume":"22","author":"Brown","year":"2016","journal-title":"Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc"},{"issue":"4","key":"10.1016\/j.jfma.2017.06.006_bib29","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jhep.2016.05.039","article-title":"Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence \u2013 the ANRS CUPILT study","volume":"65","author":"Coilly","year":"2016","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.jfma.2017.06.006_bib30","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1053\/j.gastro.2016.02.078","article-title":"Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease","volume":"150","author":"Pockros","year":"2016","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.jfma.2017.06.006_bib31","doi-asserted-by":"crossref","first-page":"e0137852","DOI":"10.1371\/journal.pone.0137852","article-title":"Rapid prediction of treatment futility of boceprevir with peginterferon-ribavirin for Taiwanese treatment experienced hepatitis C virus genotype 1-infected patients","volume":"10","author":"Yang","year":"2015","journal-title":"PloS One"},{"issue":"12","key":"10.1016\/j.jfma.2017.06.006_bib32","doi-asserted-by":"crossref","first-page":"e52048","DOI":"10.1371\/journal.pone.0052048","article-title":"Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirin","volume":"7","author":"Yu","year":"2012","journal-title":"PloS one"},{"issue":"9954","key":"10.1016\/j.jfma.2017.06.006_bib33","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(14)61059-X","article-title":"All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study","volume":"384","author":"Manns","year":"2014","journal-title":"Lancet (London, England)"},{"issue":"1","key":"10.1016\/j.jfma.2017.06.006_bib34","first-page":"132","article-title":"Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents","volume":"15","author":"Wang","year":"2017","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664617302929?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664617302929?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T01:08:52Z","timestamp":1589764132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664617302929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0929664617302929"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2017.06.006","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Paritaprevir\/ritonavir\/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1\u00a0infection after liver transplantation: Real-world experience","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2017.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}